推荐产品
生物源
mouse
品質等級
抗體表格
purified antibody
抗體產品種類
primary antibodies
無性繁殖
DO-1, monoclonal
形狀
liquid
包含
≤0.1% sodium azide as preservative
物種活性
feline, human
應無反應活性
mouse, rat
製造商／商標名
Calbiochem®
儲存條件
do not freeze
同型
IgG2a
運輸包裝
wet ice
儲存溫度
2-8°C
目標翻譯後修改
unmodified
基因資訊
human ... TP53(7157)
一般說明
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with X63Ag8.653 mouse myeloma cells (see application references). Recognizes the ~53 kDa wild-type and mutant forms of p53.
Recognizes the ~53 kDa wild-type and mutant p53 protein in A431 cells and breast carcinoma tissue.
This Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) is validated for use in Frozen sections, Immunoblotting, ICC, IP, Paraffin sections for the detection of p53 (Ab-6) (Pantropic).
免疫原
Epitope: Within amino acids 21-25 of human p53
Human
wild type, recombinant, human p53
應用
Frozen sections (1 g/ml; see application references)
Immunoblotting (0.1-1 g/ml; see application references)
Immunocytochemistry (1-2.5 g/ml; see application references)
Immunoprecipitation (1 g/ml or use Cat. No. OP43A; see application references)
Paraffin sections (1 g/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
包裝
Please refer to vial label for lot-specific concentration.
警告
Toxicity: Standard Handling (A)
外觀
In 0.05 M sodium phosphate buffer, 0.2% gelatin.
分析報告
Negative Control
SK-OV-3 cells or normal skin tissue
SK-OV-3 cells or normal skin tissue
Positive Control
A431 cells or breast carcinoma tissue
A431 cells or breast carcinoma tissue
其他說明
El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Recognizes both mutant and wild-type p53 under denaturing and non-denaturing conditions. This antibody reacts weakly with rodent p53; we do not recommend it for rodent samples. For gel shift assay, use Cat. No. OP43L resuspended in 100 μl of buffer. Wild-type p53 has a short half life and is present in low amounts in cells. For immunoprecipitation increasing the amount of sample and labeling with 35S-Met for less than or equal to 1 h will aid in visualizing wild-type p53. Antibody should be titrated for optimal results in individual systems.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
nwg
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Sadie Rice et al.
Viruses, 12(3) (2020-03-19)
Persistent infection by human papillomaviruses (HPVs), small, double-stranded DNA viruses that infect keratinocytes of the squamous epithelia, can lead to the development of cervical and other cancers. The viral oncoprotein E7 contributes to viral persistence in part by regulating host
Yuji Masuda et al.
The Journal of biological chemistry, 294(11), 4177-4187 (2019-01-17)
Ubiquitin-specific protease 7 (USP7) regulates various cellular pathways through its deubiquitination activity. Despite the identification of a growing number of substrates of USP7, the molecular mechanism by which USP7 removes ubiquitin chains from polyubiquitinated substrates remains unexplored. The present study
Surendra Sharma et al.
Virology, 518, 8-13 (2018-02-11)
Modulation of expression of noncoding RNAs is an important aspect of the oncogenic activities of high-risk human papillomavirus (HPV) E6 and E7 proteins. While HPV E6/E7-mediated alterations of microRNAs (miRNAs) has been studied in detail there are fewer reports on
Cheng-Wei Chou et al.
Scientific reports, 9(1), 20403-20403 (2020-01-02)
The p53 gene is an important tumour suppressor gene. Mutant p53 genes account for about half of all lung cancer cases. There is increasing evidence for the anti-tumour effects of statins via inhibition of the mevalonate pathway. We retrospectively investigated
Rebecca A Dagg et al.
Cell reports, 19(12), 2544-2556 (2017-06-22)
Acquisition of replicative immortality is currently regarded as essential for malignant transformation. This is achieved by activating a telomere lengthening mechanism (TLM), either telomerase or alternative lengthening of telomeres, to counter normal telomere attrition. However, a substantial proportion of some
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门